NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.

@article{Zerp2014NADDB,
  title={NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.},
  author={Shuraila F. Zerp and Conchita Vens and Ben G. J. Floot and Marcel Verheij and Baukelien van Triest},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2014},
  volume={110 2},
  pages={348-54}
}
BACKGROUND APO866 is a highly specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), inhibition of which reduces cellular NAD(+) levels. In this study we addressed the potential of NAD(+) depletion as an anti-cancer strategy and assessed the combination with radiation. METHODS The anticipated radiosensitizing property of APO866 was… CONTINUE READING